Maharashtra FDA cancelled Cipla’s Pune unit drug sale licences. Serious irregularities in storage and recall procedures were cited by the regulator. The company failed to fully comply with market recall directions for Reactin Plus Tablets. Further non-compliance was discovered in the unit’s distribution and sales system.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.